Complain about a product or service

FDA Seizes More Contaminated Heparin

Ohio doctors outraged after seizure in Cincinnati

November 10, 2008

Drug Safety • FDA Cracks Down on Web Sites Selling Unapproved Drugs • FDA Unveils Safe Medication Use Program • Bayer Hit With Suit Over Prostate Claims • Feds Seize Alleged Seizure-Inducing Drugs • Matrixx Failed to Give FDA 800 Zicam Complaints • Matrixx Initiatives Pulls Zicam Products • FDA Issues Warning About Zicam Cold Remedy • FDA Issues Warning About Clarcon Skin Products • FDA Requires Additional Warning For OTC Pain Relievers • NY Mandates Multi-Lingual Rx Labels, Counsel • Two Firms Stopped From Making Unapproved Drugs • Supreme Court Upholds Consumers' Right to Sue Drug Companies In State Court • Psoriasis Drug Linked To Three Deaths • Bayer Agrees to Correct Misleading Information about Yaz • FDA Urged to Ditch Darvon • FDA Warns of Skin Numbing Product Dangers • Bayer Pays $97 Million to Settle Kickback Charges • FDA Seizes More Contaminated Heparin • FDA Warns Bayer on "Illegal" Drugs • Feds Seize More Than $24 Million in Unapproved New Drugs • Consumers Increasingly Exposed to Counterfeit Drugs • FDA Wants Black Box Warning on Antibiotics • Public Citizen Sues FDA for Failure to Act on Darvon • FDA Probes Arthritis Drug Link To Cancer • FDA Wants New Labeling Rules To Protect Pregnant, Nursing Women • Anti-Smoking Drug Chantix Linked to Seizures, Heart Problems, Diabetes • Bayer Pulls Trasylol From Market • MIT Researchers Confirm Contamination in Heparin • Be Careful Using Over-the-Counter Creams, Ointments • Another Heparin Producer Announces a Recall • FDA Moves Closer To Setting Up Shop In China • Study Raises Concerns About Anemia Drugs • Congress Hears Warnings about FDA • China Connection in Heparin Problems? • Heparin Linked to Severe Allergic Reactions • Antibiotic Leads to Tendon Ruptures • Second Safety Warning on Fentanyl Skin Patch • Merck Recalls Children's Vaccines • Study: Avandia May Do More Harm than Good • Texas Sues Drug Manufacturer Blamed for West Coast Deaths • Bayer Withdraws Antibleeding Drug Trasylol --- • More drug safety news ...

Ten months after recalling large amounts of the Chinese blood-thinning drug heparin because of contamination, the U.S. Food and Drug Administration has discovered some of it is still on the market.

In response, U.S. Marshals seized five lots of Heparin Sodium Active Pharmaceutical Ingredient (API) and six lots of Heparin Lithium from Celsus Laboratories Inc. in Cincinnati.

These products, which were manufactured from material imported from China, had been found by the agency to be contaminated with over-sulfated chondroitin sulfate (OSCS), a substance that mimics heparin's anticoagulant activity.

"This action will help prevent this contaminated heparin from finding its way into the marketplace," said Mike Chappell, acting associate commissioner for regulatory affairs, FDA.

Doctors outraged

WTOL-TV in Toledo interviewed a number of Ohio doctors who expressed shock and outrage at the revelations.

"It's really horrible for two reasons: one, that a company that knows that their product is not a good product that should be distributed and they've been told so," said Dr. Lynne Wagoner, a Christ Hospital Heart Specialist. "This contaminate called chondrotin sulfate, when combined with heparin, has a super additive effect, so that's leading to strokes."

Heparin is a blood-thinning drug. An API is a substance or mixture of substances that, when delivered in a finished drug product, directly affects the structure or function of the body. Heparin Sodium USP is an API that may be incorporated into finished drug products.

Heparin Lithium is used in certain medical devices including vacutainer blood collection tubes, some in vitro diagnostic assays, and as a coating for capillary tubes. Celsus has distributed Heparin Sodium USP and Heparin Lithium to manufacturers in both the United States and abroad.

Multiple problems

OSCS contaminant in injectable drug products containing heparin has been linked to multiple adverse events and deaths initially reported to the FDA in January 2008.

Since then, the FDA has put in place a comprehensive inspection and import controls program and has acted to remove from the market heparin materials and products contaminated with OSCS. The seized Celsus heparin – which had entered the United States before the establishment of import controls for the drug – was tested for the presence of OSCS as part of this FDA effort.

To date, the agency has initiated 13 recalls of multiple contaminated medical products containing heparin from several companies.

The FDA said it informed Celsus Laboratories during an April 2008 inspection and again in a May 8, 2008, letter that the company's actions to notify customers about a contaminant in its heparin were insufficient to assure an effective recall.

The agency advises manufacturers who may have purchased heparin from Celsus to contact the company to make certain they are not using any heparin from the seized lots because the product does not meet acceptable quality standards.

The FDA has notified Japanese, Canadian, Australian, European Union, and other international authorities of shipments of contaminated heparin from Celsus.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.